TW201728352A - Drug releasing and detecting device, operating method thereof, and detecting fluorescent substance method connecting a detecting tube with one end of each of a drug delivery tube, a fluorescent tube and an optical fiber - Google Patents

Abstract

A drug releasing and detecting device comprises a detecting tube which is assembled with one end of each of a drug delivery tube, a fluorescent tube and an optical fiber and is utilized to enter a to-be-detected substance so that a drug can pumped to the to-be-detected substance by a first syringe pump via the drug delivery tube. The fluorescent tube connected with a second syringe pump is utilized to deliver a first fluorescent substance and a second fluorescent substance, in which the first fluorescent substance is diffusively attached to a space environment cell in the to-be-detected substance, and the second fluorescent substance is diffusively attached to a not-to-be-detected autologous cell with specific physiological activity in the to-be-detected substance. The optical fiber signally connected with a spectrograph is used for stimulating the drug in the to-be-detected substance for releasing and detecting the diffusion concentrations of the first and second fluorescent substances at a wavelength different from that of the optical fiber, and the spectrograph is used for analyzing the concentration distribution of the first and second fluorescent substances.

Description

Drug release and detection device, method for operating drug release and detection device, and method for detecting fluorescent material

The present invention relates to a drug release and detection device, a method of operating a drug release and detection device, and a method of detecting a phosphor.

Clinically, it is usually through imaging examination (X-ray, ultrasound, computed tomography CT, MRI, MRI, etc.) and endoscopy to infer the location of the tumor, and then use the puncture or clip to take the lesion. The organization does a pathological biopsy. The final diagnosis still depends on sampling directly from the lesion site (slice or surgically removed tumor tissue), staining and performing histopathological examination under the microscope, and then relying on it as a further treatment.

The above-mentioned computerized tomography for the detection of benign and malignant tumors is currently a widely diagnosed method, but it is limited by the fact that the developer cannot be effectively accumulated into the malignant tumor, and it has the effect of reducing the degree of peripheral contrast and is not easy to present irregular shape characteristics, and is easily misjudged as a benign tumor. Increase the risk of cancer deaths. By using an iodine-containing developer for injection and drinking, the x-ray absorbance can be increased, so that the medical staff can observe the functional state of the patient's organs or tissues. Traditionally, the developer is filtered by the kidney to form urine and discharged outside the patient's body. However, in elderly patients, diabetics, and patients with renal insufficiency, it is prone to accumulation of a large amount of developer in the kidney to cause acute renal failure.

Subsequent cancer treatments include surgical treatment of surgically resecting tissues invaded by cancer cells, or injection of drugs into the patient's body by injection or oral administration to kill cancer cells or inhibit cancer cell expansion, and radiation exposure to cancer patients. Radiation therapy to kill cancer tissue. There are more targeted treatments for the specific performance of cancer cells or the deterioration of metastasis. Regardless of the treatment method, the above-mentioned imaging examination is still needed after the treatment, and the effect of the treatment is confirmed, and the reference for selecting the medicine, administration, dosage, and even follow-up treatment of the diagnostician is provided. Therefore, the process of treatment and lesion examination is troublesome and time consuming, often bringing physical and mental pain and anxiety to the patient.

The present invention provides a drug release and detection device that solves the aforementioned problem of using a developer, and simultaneously detects the treatment condition after re-administration.

A detection tube is assembled with one end of a drug delivery tube, a fluorescent tube and an optical fiber, and the detection tube enters the object to be tested; wherein the other end of the drug delivery tube is connected to the syringe pump, and the medicament is pumped by the syringe to the drug delivery tube. The other end of the fluorescent tube is connected to the syringe pump, and the first phosphor and the second phosphor are transported, and the first phosphor diffuses and adheres to the space environment cells in the object to be tested, and the second phosphor Spreading and attaching to the specific physiologically active non-subject self-cell in the test object; the other end of the optical fiber is connected to the spectrometer, and the drug is excited by the optical fiber to be excited in the test object, and the first fluorescent light is sensed differently from the wavelength of the optical fiber. The concentration of the first and second phosphors is analyzed by a spectrometer.

The aforementioned drug release and detection device, wherein the first fluorescent substance is 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, and the second fluorochrome FM 1-43.

The aforementioned drug release and detection device, wherein the agent comprises AuNP-embedded liposomes, and the AuNP-embedded liposomes are coated with a maximum of 75 mM fluorescein (self-quench) Concentration; self-extinguishing concentration fluorescent indicator) and cyclophosphamide (cyclophosphamide). The AuNP-embedded liposomes of the medicaments were selected from the concentration range of 16 to 66 ng/ml (Nike/ml).

The above drug release and detection device, wherein the environmental cell line is a homogeneous part of the test substance, and the specific physiological activity specific cell line is a non-homogeneous part of the self-test substance.

The drug release and detection device described above, wherein the first phosphor and the second phosphor are diffused by the syringe pump through the fluorescent tube to the analyte simultaneously or separately.

The method for operating the drug release and detection device comprises the following steps: (a) first injecting the drug into the test object through the drug delivery tube through the drug delivery tube; (b) exciting the object to be tested with the fiber light guiding 65 mW 532 nm. The drug in the drug releases the fixed point position; (c) the syringe pump delivers the first phosphor and the second phosphor to inject the object to be tested, and the first phosphor diffuses into the space environment cells in the object to be tested for spatial distribution, and The second phosphor is diffused in the unanticipated self-cell of the test object, and the second phosphor is adsorbed by the non-subject self cell; (d) after the optical fiber is different from the aforementioned excitation agent, Two phosphors are excited to sense and are analyzed by a spectrometer at the object to be tested The location of the first phosphor reaction signal distribution in the internal space environment, and the location of the second phosphor reaction signal distribution in the non-self cell in the analyte. After the step (d) is completed, the cycle mode is sequentially performed by the step (a).

A method for detecting a fluorescent substance, comprising: a detecting tube of the drug releasing and detecting device, sensing a divergence concentration of the first and second fluorescent substances by the optical fiber of the detecting tube, and analyzing the first and second fluorescent lights through the spectrometer Object to form the first and second phosphor fluorescence spectral ratios.

1‧‧‧Test tube

2‧‧‧Dose tube

3‧‧‧ fluorescent tube

4‧‧‧Fiber

5‧‧‧Syringe pump

6‧‧‧Syringe pump

7‧‧‧ Spectrometer

The first figure is a schematic view of the drug release and detection device of the present invention.

The second figure is a schematic diagram of the present invention penetrating into the subcutaneous tissue and entering the tumor range, and performing drug release and fiber-exciting drugs.

The third panel is the AuNP-embedded liposomes of the present invention coated with 75 mM fluorescein (self-extinguishing fluorescence indicator) fluorescing in nude mice before and after receiving a fiber laser, time and fluorescence response profile Figure.

The fourth panel is a graph showing the value/time curve of the fluorescence response in the tumor using AuNP-embedded liposomes coated with 75 mM fluorescein (self-extinguishing fluorescence indicator).

Referring to the first figure of the figure, the drug release and detection device of the present invention comprises a detection tube 1, a drug delivery tube 2, a fluorescent tube 3, an optical fiber 4, a syringe pump 5, 6, and a spectrometer 7.

The detecting tube 1 is assembled and covered with the drug delivery tube 2, the fluorescent tube 3 and the optical fiber 4, so that they can be collectively assembled at one end, so that the subsequent fixed-point drug is released and detected at the same position of the object to be tested. The aforementioned drug delivery tube 2 and the fluorescent tube 3 are capillary tubes. The detection tube 1 is used as a puncture object to be tested, in addition to the use of the collection and delivery tube 2, the fluorescent tube 3, and the optical fiber 4.

The end of the drug delivery tube 2 is connected to the syringe pump 5. The syringe pump 5 is provided with a syringe, and the filling agent in the syringe includes AuNP-embedded liposomes and other solutions such as a buffer, and the syringe is connected to the drug delivery tube 2 and is transfused. The drug tube 2 is delivered. The AuNP-embedded liposomes of the drug were selected from the concentration range of 16 to 66 ng/ml (Nike/ml), and the maximum coverage of AuNP-embedded liposomes was not more than 75 mM fluorescein (self-quench concentration; self-quenching fluorescent indicator) and cyclophosphamide (cyclophosphamide), the aforementioned AuNP-embedded liposomes having a particle size of 100 to 600 nm (nano).

One end of the fluorescent tube 3 is connected to the syringe pump 6. The illustration shows that the syringe pump 6 is provided with two syringes, which are respectively filled with the first and second phosphors, and the syringe is connected with the fluorescent tube 3 at the end of the fluorescent tube 3 and has two joint ends respectively. Two syringes can be connected, and two syringes can be connected by two fluorescent tubes 3.

The aforementioned first phosphor is Marina Blue 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, and the second phosphor FM 1-43.

The syringe pumps 5 and 6 mentioned above provide syringe erection, both A timing quantitative control mechanism is used to push the syringe to control the flow control and total output in the syringe.

One end of the optical fiber 4 is connected to the spectrometer 7 signal, and the spectrometer 7 has a laser light source. The optical fiber of this embodiment used an inner diameter of 200 μm.

To further illustrate the method of operation of the drug of the present invention release the detection means, based in nude mice in vivo experiments and prior values into malignant tumor (MDA-MB 231 cell / matrigel TM) and allowed to grow to 2mm at 1mm, the present embodiment of the system to The nude mouse is the test object and the living anesthesia is performed before the following method is performed. The method steps include the following records (a) to (d), wherein:

(a) The drug is first injected into the malignant xenograft (MDA-MB 231 cell/matrigelTM ^{) of the} test object via the drug delivery tube 2 (point of administration), as indicated by the arrow in the second figure. The drug AuNP-embedded liposomes contains 75 mM fluorescein (self-quench concentration), so that the subsequent experimental control contains 75 mM fluorescein and is not contained in the test substance. Fluorescent reaction.

(b) Excitation of the drug in the test object by the optical fiber 4 light guide 65mW532nm to promote the release and sense the fixed-point release position, and the AuNP-embedded liposomes located in the test object is excited by the light guiding light 65mW532nm. (body), and convert the light energy into heat energy, and the temperature changes to the critical temperature of the permeability phase change, promoting the release of the drug (fixed release position) efficiency, while releasing 75 mM fluorescein, as indicated in the second figure 75 mM. Please refer to the upper part of the third figure, through its image representation in AuNP-embedded liposomes The plastids are imaged before and after laser excitation, including pre-excitation, post-excitation, excitation for 60 minutes, and excitation for 120 minutes. The fluorescence reaction is reflected at the position and changes from the beginning to 120 minutes, from initial to 10 The minute is the maximum value, and the fluorescence reaction range is reduced from 10 minutes later, and it is maintained after a sharp decline between 60 minutes and 120 minutes. Further, the lower part of the third figure is a numerical contour map. And comparing the ratios of the fluorescence reaction before and after the excitation, after excitation for 60 minutes and excitation for 120 minutes, respectively, are presented in equal regions. Please refer to the fourth figure. There are two curves: solid line and dotted line. The solid line represents AuNP-embedded liposomes containing 75 mM fluorescein, while the dotted line represents AuNP-embedded liposomes. The liposome did not contain 75 mM fluorescein, and the dashed curve showed a slight decline in the acceptance of the fiber laser, which was less than 1 (tumor fluorescence response value), while the solid curve appeared 10 minutes after the laser excitation of the receiving fiber. Fluorescence showed nearly 1.5 (tumor fluorescence response) in malignant xenografts, and the solid curve remained in the range of 0.4 to 0.5 from 60 minutes to 120 minutes.

It is concluded that AuNP-embedded liposomes contain 75 mM fluorescein, which is suitable for the effective release of the drug and the release of specific site sensing, and can instantly monitor the range of drug effect diffusion. Furthermore, its self-destruction over time can effectively reduce the false positive environmental factors for the subsequent detection of the next drug release.

(c) The syringe pump 6 is equipped with two syringes filled with first or second phosphor timing or quantitative or a combination of the two, and the first and second phosphors are transported through the fluorescent tube 3, and first The fluorescent substance and the second fluorescent substance will be injected into the malignant transplantation of the test object The tumor is spatially distributed through the first fluorescent substance diffusing, adhering or even entering the space environment cells in the object to be tested, and the second fluorescent substance diffuses, adheres to and even enters the self-test cell of the non-subject substance in the test object (malignant transplanted tumor) ).

(d) after the fiber 4 is excited by the wavelength of the laser different from the excitation agent, the first and second phosphors are excited and returned to the spectrometer 7 to analyze the first phosphor reaction in the space environment of the object to be tested. Position of the signal distribution, and analysis of the distribution position of the second fluorescent substance reaction signal located in the physiological activity of the non-self cell (malignant xenograft) in the test object; thus, the first and second fluorescent light can be sensed by the optical fiber 4 of the detection tube 1. Fluorescence spectrum divergence concentration, and feedback to spectrometer 7 to analyze the first and second phosphors to form the first and second phosphor fluorescence spectral ratios, thereby sensing the second fluorescent material represented by the malignant tumor cells The condition of apoptosis, the boundary range of malignant xenografts, and the size of malignant xenografts can be sensed and monitored immediately. Therefore, when the present invention is applied to the human body, there is no problem of using the developer in the past, and the treatment can be detected immediately after administration.

The method for operating the drug release and detection device described above, wherein after the step (d), the cycle mode is sequentially performed by the step (a) to provide the cycle or number of cycles selected by the medical staff according to the lesion and the condition of the patient.

1‧‧‧Test tube

2‧‧‧Dose tube

3‧‧‧ fluorescent tube

4‧‧‧Fiber

5‧‧‧Syringe pump

6‧‧‧Syringe pump

7‧‧‧ Spectrometer

Claims (9)

A drug release and detection device comprises: a detection tube assembled with a drug delivery tube, a fluorescent tube and an optical fiber, and the detection tube enters the object to be tested; wherein the other end of the drug delivery tube is connected to the syringe pump, and the medicament is used by the syringe The pump passes through the drug delivery tube to the test object; the other end of the fluorescent tube is connected to the syringe pump, and the first phosphor and the second phosphor are transported, and the first phosphor is diffused and adhered to the space environment of the object to be tested. a cell, and the second fluorescent substance is diffused and attached to the specific physiologically active non-test substance itself in the test object; the other end of the optical fiber is connected to the spectrometer, and the agent excited by the optical fiber in the test object is released, and is different from the aforementioned optical fiber. The first phosphor and the second phosphor diffusion concentration are sensed by the wavelength, and the first and second phosphor concentration distributions are analyzed by the spectrometer. The drug release and detection device of claim 1, wherein the first phosphor is 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine and the second phosphor FM 1-43. The drug release and detection device according to claim 1 or claim 2, wherein the agent comprises AuNP-embedded liposomes, and AuNP-embedded liposomes are coated with The maximum does not exceed 75 mM fluorescein (self-quench concentration; self-quenching fluorescent indicator) and cyclophosphamide (cyclophosphamide). The drug release and detection device according to claim 3, wherein the AuNP-embedded liposomes of the agent is selected from 16 to 66 ng/ml. (Nike / ml). The drug release and detection device according to claim 1, wherein the environmental cell line is a homogeneous part of the test substance, and the specific physiological activity specific cell line is a non-homogeneous part of the self-test substance. The drug release and detection device according to claim 1, wherein the first phosphor and the second phosphor are simultaneously or separately diffused by the syringe pump through the fluorescent tube to the analyte. The method for operating the drug release and detection device of claim 1, comprising the steps of: (a) first injecting the drug into the test object through the drug delivery tube through the drug delivery tube; (b) stimulating the fiber to be guided by the light guide 65mW532nm. The reagent in the test object releases the fixed point position; (c) the syringe pump delivers the first phosphor and the second phosphor to inject the object to be tested, and the first phosphor diffuses into the space environment cells in the object to be tested for spatial distribution. The second fluorescent substance is diffused in the non-subject self-cell of the test object, and the second fluorescent substance is adsorbed by the non-subject self-cell; (d) the optical fiber is different from the aforementioned excitation agent by the optical fiber. The first and second phosphors are excited to sense, and the first fluorescent material reaction signal distribution position in the space environment of the object to be tested is analyzed by a spectrometer, and the second fluorescence of the physiological activity in the non-self cell in the object to be tested is analyzed. The location of the signal response signal. The operation method of claim 7, wherein the loop mode is sequentially performed by the step (a) after the step (d) is finished. A method for detecting a fluorescent material, comprising: detecting a first and second phosphors by a spectrometer, by sensing a tube of the detecting tube, sensing a diffracted concentration of the first and second phosphors by a fiber of the detecting tube; To constitute the first and second fluorescent material fluorescence spectral ratio.